NASDAQ
PRTG

Portage Biotech Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Portage Biotech Inc Stock Price

Vitals

Today's Low:
$2.575
Today's High:
$2.76
Open Price:
$2.575
52W Low:
$2.3
52W High:
$8.327
Prev. Close:
$2.69
Volume:
1794

Company Statistics

Market Cap.:
$47.00 million
Book Value:
4.141
Revenue TTM:
$0
Operating Margin TTM:
0%
Gross Profit TTM:
$0
Profit Margin:
0%
Return on Assets TTM:
-7.17%
Return on Equity TTM:
-91.7%

Company Profile

Portage Biotech Inc had its IPO on 2021-02-25 under the ticker symbol PRTG.

The company operates in the Healthcare sector and Biotechnology industry. Portage Biotech Inc has a staff strength of 7 employees.

Stock update

Shares of Portage Biotech Inc opened at $2.58 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $2.58 - $2.76, and closed at $2.64.

This is a -1.86% slip from the previous day's closing price.

A total volume of 1,794 shares were traded at the close of the day’s session.

In the last one week, shares of Portage Biotech Inc have increased by +12.34%.

Portage Biotech Inc's Key Ratios

Portage Biotech Inc has a market cap of $47.00 million, indicating a price to book ratio of 0.5308 and a price to sales ratio of 0.

In the last 12-months Portage Biotech Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-15775000. The EBITDA ratio measures Portage Biotech Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Portage Biotech Inc’s operating margin was 0% while its return on assets stood at -7.17% with a return of equity of -91.7%.

In Q2, Portage Biotech Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Portage Biotech Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-6.44 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Portage Biotech Inc’s profitability.

Portage Biotech Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -4.1562. Its price to sales ratio in the trailing 12-months stood at 0.

Portage Biotech Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$99.13 million
Total Liabilities
$1.87 million
Operating Cash Flow
$0
Capital Expenditure
$0
Dividend Payout Ratio
0%

Portage Biotech Inc ended 2024 with $99.13 million in total assets and $0 in total liabilities. Its intangible assets were valued at $99.13 million while shareholder equity stood at $76.05 million.

Portage Biotech Inc ended 2024 with $0 in deferred long-term liabilities, $1.87 million in other current liabilities, 218782000.00 in common stock, $-159616000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $10.55 million and cash and short-term investments were $10.55 million. The company’s total short-term debt was $47,000 while long-term debt stood at $0.

Portage Biotech Inc’s total current assets stands at $13.68 million while long-term investments were $4.61 million and short-term investments were $0. Its net receivables were $682000.00 compared to accounts payable of $274000.00 and inventory worth $0.

In 2024, Portage Biotech Inc's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Portage Biotech Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$2.64
52-Week High
$8.327
52-Week Low
$2.3
Analyst Target Price
$10

Portage Biotech Inc stock is currently trading at $2.64 per share. It touched a 52-week high of $8.327 and a 52-week low of $8.327. Analysts tracking the stock have a 12-month average target price of $10.

Its 50-day moving average was $2.91 and 200-day moving average was $3.8 The short ratio stood at 0.62 indicating a short percent outstanding of 0%.

Around 4061.1% of the company’s stock are held by insiders while 108.9% are held by institutions.

Frequently Asked Questions About Portage Biotech Inc

The stock symbol (also called stock or share ticker) of Portage Biotech Inc is PRTG

The IPO of Portage Biotech Inc took place on 2021-02-25

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$98.8
-8.3
-7.75%
$0.27
0.08
+42.45%
GTLS-P-B (GTLS-P-B)
$69.21
-0.05
-0.07%
$173.35
-6
-3.35%
$62.1
1.33
+2.19%
$243
-0.4
-0.16%
IMI PLC (IMIAY)
$35.2
0.57
+1.65%
$18.91
-0.21
-1.1%
$10.8
-0.04
-0.37%
$17.15
0.12
+0.7%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Portage Biotech Inc., together with its subsidiaries, research and develops pharmaceutical and biotechnology products. The company’s product pipeline includes IMM60, an iNKT cell activator that is in phase I clinical trial; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; TT-4, an adenosine receptor type 2B (A2B) inhibitor to treat solid tumors; TT-53, an A2A/A2B inhibitor to treat solid tumors; TT-10, an adenosine receptor type 2A (A2A) inhibitor to treat A2A expressing solid tumors; TT-3, an A2B inhibitor to treat colorectal and gastrointestinal cancers; and INT230-6 for the treatment of tumors. It also provides Nanolipogel co-formulation platform for delivery of DNA aptamers and certain aptamer-small molecule-based combination products; and STING agonist platform, a proprietary immune priming and boosting technology, offers various ways to target immune stimulation towards the cancer, as well as to co-deliver various signals in a single product. The company is based in Tortola, British Virgin Islands.

Address

Craigmuir Chambers, Tortola, British Virgin Islands, VG1110